Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Rhea-AI Summary
Regeneron (NASDAQ: REGN) announced a strategic collaboration with TriNetX to access TriNetX’s de-identified EHR network of approximately 300 million patients (about 170 million in the U.S.). Regeneron gains an exclusive opportunity to link RGC genomic and proteomic cohorts to this phenotypic dataset.
The deal enables expansion of Regeneron Genetics Center’s EHR-linked database, supports AI training for digital health solutions, and includes a Regeneron investment of up to $200 million. Data matching will follow applicable privacy laws including HIPAA and GDPR.
Positive
- Access to 300M de-identified EHR records
- Exclusive opportunity to connect genomic/proteomic cohorts
- Expansion of RGC EHR-linked database to drive discovery
- Up to $200M investment demonstrates strategic commitment
Negative
- Up to $200M investment creates material capital exposure
News Market Reaction – REGN
On the day this news was published, REGN gained 0.16%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
REGN is up 0.6% while close biotech peers show mixed moves: ALNY -1.29%, VRTX -1.97%, versus ARGX +1.49%, ONC +1.1%, INSM +0.57%. No broad, synchronized sector trend is evident.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Earnings call date | Neutral | +1.0% | Scheduled Q1 2026 results release and investor webcast announcement. |
| Mar 24 | Drug approval | Positive | +0.7% | Dupixent approval in Japan for bullous pemphigoid, expanding indications. |
| Mar 10 | STEM initiative | Neutral | +0.3% | Science Talent Search awards and extended STEM sponsorship commitment. |
| Mar 09 | Clinical trial data | Positive | +2.9% | Positive Phase 3 obesity trial results for olatorepatide in Chinese patients. |
| Mar 05 | Conference presentation | Neutral | -0.7% | Announcement of management presentation at a major healthcare conference. |
Recent REGN news, especially clinical and regulatory milestones, has generally been followed by modest positive price reactions, suggesting the market has responded constructively to fundamental updates.
Over the past month, Regeneron has reported several favorable developments. A Mar 9 obesity trial update showed strong Phase 3 results with solid weight loss outcomes and the stock rose 2.86%. A Mar 24 Japanese approval for Dupixent also saw a positive reaction. Other items, like conference/webcast announcements and the Regeneron Science Talent Search awards, produced smaller moves. Today’s partnership fits into this pattern of strategic and R&D-focused news supporting the broader pipeline and data capabilities.
Market Pulse Summary
This announcement highlights a strategic data and AI collaboration, giving Regeneron secure access to de-identified EHR data from about 300 million patients, including 170 million in the U.S., and involving up to $200 million in investment. Combined with its existing RGC platform and strong 2025 financial base ($14,342.9M revenue, $4,504.9M net income), the deal expands large-scale datasets for drug discovery and digital health. Investors may watch how effectively these data assets translate into pipeline advances and new solutions.
Key Terms
electronic health record medical
ehr medical
genomic medical
proteomic medical
hipaa regulatory
gdpr regulatory
artificial intelligence technical
de-identified technical
AI-generated analysis. Not financial advice.
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data
Collaboration will expand Regeneron’s world-leading genomic and proteomic EHR-linked database
Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providers
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and TriNetX® today announced a strategic collaboration to support Regeneron’s capabilities in drug discovery and development, as well as new initiatives to deliver digital health solutions of the future for consumers, patients and providers. Regeneron gains the exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading phenotypic data network of approximately 300 million de-identified and anonymized patients. This collaboration will enable expansion of Regeneron’s world-leading genomic and proteomic Electronic Health Record (EHR)-linked database, a key driver of the company’s industry-leading therapeutics pipeline.
Under the collaboration, TriNetX will provide Regeneron with secure, licensed access to TriNetX’s current and future de-identified health data from approximately 300 million individuals (170 million of whom are in the United States), sourced directly from its global network of health system partners. With privacy-preserving methods, Regeneron will have the capability to match a portion of TriNetX’s de-identified/anonymized data to genomic and proteomic data generated by the Regeneron Genetics Center® (RGC®). Such matching will be conducted in accordance with all applicable data privacy laws, including HIPAA and GDPR.
The RGC has developed high-throughput and cost-efficient DNA sequencing and proteomics approaches to build the world’s largest database of EHR-linked sequencing and proteomics data, in collaboration with over 150 life sciences and healthcare collaborators around the world. The collaboration with TriNetX will help Regeneron dramatically expand this already world-leading dataset to continue to drive drug discovery and development, while also empowering artificial intelligence (AI) training algorithms to deliver digital health solutions of the future.
“We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data,” said Jeff Margolis, TriNetX Executive Chairman. “Our team is gratified to be selected by Regeneron to provide access to TriNetX’s unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centers and other leading healthcare research sites.”
"This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers," said Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines. "TriNetX has built a world-leading platform with a proven track record of enabling research at scale. The RGC has spent over a decade generating genomic and now proteomic data and integrating these molecular data with longitudinal health records at large-scale. Combining these platforms brings together powerful human health databases with analytical and AI capabilities to help discover and develop innovative medicines for devastating diseases and create digital health solutions that we hope will transform our ability to predict, prevent and manage disease."
"We are looking forward to working with the TriNetX team," said Andrew Deubler, Senior Vice President, RGC Chief Business and Administrative Officer. "Our RGC strategic investments catalyze innovation, driving advancements in cutting-edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions. This deal represents the latest and one of our most significant collaborations, and we look forward to continuing to expand our network of top-tier partners as we pursue our mission."
As part of the collaboration, Regeneron will invest up to
About TriNetX, LLC
TriNetX is the Global Truth Engine for Better Human Health™ that makes complex, real-world health data easy to use. Data is sourced directly from our growing global network of over 11,000 healthcare provider locations. TriNetX customers select the data source, types, and breadth of data they need; the data access methods they desire; and the types of software, human and machine intelligence they wish to apply – and combine these to solve their business objectives. Visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn to learn more.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook, YouTube or X.
About the Regeneron Genetics Center
The Regeneron Genetics Center® (RGC®) is a genomic research initiative and a wholly owned subsidiary of Regeneron. For over a decade, we have harnessed the power of human genetics to discover important new medicines, validate existing research programs and optimize clinical trials. We tap into our growing database of more than 3 million sequenced exomes and de-identified health information using proprietary data analytics, technology and human ingenuity to make meaningful biological discoveries at speed and scale. Our high-touch integrated model focuses on working closely with our collaborators to build a dataset with meaningful cohorts. We use innovative technologies, such as machine learning, to sequence exomes, align with health information and perform large-scale analyses to make meaningful associations between genes and diseases. We apply our insights to guide Regeneron’s broader drug discovery and development efforts.
Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”), research and clinical programs now underway or planned, and the use of human genetics in Regeneron's research programs; the likelihood, timing, and scope of achieving any of the anticipated milestones described in this press release; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (such as those that may result from Regeneron’s collaboration with TriNetX discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) as well as the collaboration with TriNetX discussed in this press release, to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).
Regeneron
Media:
Ella Campbell
Email: ella.campbell@regeneron.com
Investors:
Vesna Tosic
Email: vesna.tosic@regeneron.com
TriNetX
Karen Tunks
Email: Karen.Tunks@TriNetX.com
